Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants
In conclusion, oral famitinib bioavailability is not affected by food intake, implying that patients with cancer do not need to consider dietary status when using famitinib. This is considered important for convenience and treatment compliance.
Source: Clinical Pharmacology in Drug Development - Category: Drugs & Pharmacology Authors: Xiaoran Zhang,
Gexin Shi,
Shaorong Li,
Jing Rao,
Qing Wen,
Hengli Zhao Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Diets | Drugs & Pharmacology | High Fat | Nutrition | Oral Cancer | Study